294 results on '"Reichard, Kaaren K"'
Search Results
2. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events
3. Updates on eosinophilic disorders
4. Pulmonary manifestations in VEXAS syndrome
5. Clinicopathologic correlates and prognostic impact of lymphoid aggregates in patients with myelodysplastic syndromes.
6. Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases
7. Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted
8. Erythroblastic sarcoma transformation from a chronic myeloid neoplasm with FGFR1 rearrangement presenting as a pleural effusion: a case report
9. PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis.
10. Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1
11. p53 immunohistochemistry discriminates between pure erythroid leukemia and reactive erythroid hyperplasia
12. Comprehensive morphologic characterization of bone marrow biopsy findings in a large cohort of patients with VEXAS syndrome: A single-institution longitudinal study of 111 bone marrow samples from 52 patients.
13. Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia
14. Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis
15. Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
16. Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients
17. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients
18. TP53 variant allele frequency and therapy‐related setting independently predict survival in myelodysplastic syndromes with del(5q).
19. De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity
20. Now You See Me: Acute and Recurrent Severe Abdominal Pain Associated With Bowel Edema
21. Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia
22. The significance of genetic mutations and their prognostic impact on patients with incidental finding of isolated del(20q) in bone marrow without morphologic evidence of a myeloid neoplasm
23. VEXAS syndrome: Clinical, hematologic features and a practical approach to diagnosis and management.
24. Mast cell cytomorphology and treatment outcome in mast cell leukemia.
25. Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases.
26. Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome.
27. High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations
28. Targeted testing of bone marrow specimens with cytoplasmic vacuolization to identify previously undiagnosed cases of VEXAS syndrome.
29. Laboratory Test Utilization Management: General Principles and Applications in Hematopathology
30. World Health Organization class-independent risk categorization in mastocytosis
31. Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations
32. Scoring of MYC protein expression in diffuse large B-cell lymphomas: concordance rate among hematopathologists
33. Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS)
34. Correction to: Hybridization capture-based next-generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis
35. Isolated trisomy 2 in bone marrows of patients with suspected hematopoietic malignancies
36. Crystal-Storing Histiocytosis in Bone Marrow: A Clinicopathologic Study of Eight Cases and Review of the Literature
37. Blastic Plasmacytoid Dendritic Cell Neoplasm: How do You Distinguish It from Acute Myeloid Leukemia?
38. TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo‐Moffitt study of 156 informative cases.
39. Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML
40. Pediatric B-lymphoblastic leukemia with RUNX1 amplification: clinicopathologic study of eight cases
41. Is It Time for a New Gold Standard? FISH vs Cytogenetics in AML Diagnosis
42. Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients.
43. Pilot Prospective Study of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Vexas Syndrome
44. Conventional Karyotyping and Fluorescence In Situ Hybridization: An Effective Utilization Strategy in Diagnostic Adult Acute Myeloid Leukemia
45. Antineutrophil cytoplasmic antibody–associated vasculitis and VEXAS syndrome: comment on the article by Muratore et al.
46. Typical, atypical and cryptic t(15;17)(q24;q21) (PML::RARA) observed in acute promyelocytic leukemia: A retrospective review of 831 patients with concurrent chromosome and PML::RARA dual‐color dual‐fusion FISH studies.
47. Novel USP25::PDGFRA Gene Fusion in a 78 Year Old Patient with a Myeloid Neoplasm.
48. TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)
49. ASXL1 Mutation and Leukocytosis Undermine Spleen Response to Pacritinib in Myelofibrosis
50. Sodium-Glucose Co-Transporter-2 Inhibitor Use in the Setting of Myeloproliferative Neoplasms: Impact on Hemoglobin/Hematocrit Levels and Thrombosis Risk
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.